Reyvow Tablets
Lasmiditan
100 mg
ELI LILLY AND COMPANY
| Pack size | 4’s Blister |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | PHARMATRADE |
| Retail Price | 1585.00 AED |
Available as:
Indications
Reyvow Tablets is used for:
Acute Migraine
Adult Dose
Acute Migraine
Indicated for treatment of acute migraine with or without aura
50 mg, 100 mg, or 200 mg PO PRN
Not to exceed more than 1 dose/24 hr
Do not take unless patient can wait at least 8 hr between dosing and driving or operating machinery
Second dose has not been shown to be effective for the same migraine attack
The safety of treating an average of >4 migraine attacks/30 days has not been established
Hepatic impairment
Mild or moderate (Child-Pugh A or B): No dosage adjustment needed
Severe (Child-Pugh C): Not recommended
Child Dose
Renal Dose
Renal impairment
No dosage adjustment needed for any degree of renal impairment
Administration
May take with or without food
Contra Indications
Precautions
CNS depression (eg, dizziness, sedation) reported
Significant driving impairment may occur; advise patients not to engage in potentially hazardous activities requiring complete mental alertness eg, driving a motor vehicle, operating machinery) for at least 8 hr after each dose; avoid use in patients who are unable to follow this advice
Reactions consistent with serotonin syndrome reported; discontinue if symptoms of serotonin syndrome occur
Overuse of acute migraine drugs (eg, ergotamines, triptans, opioids, or a combination of these drugs for ≥10 per month) may lead to exacerbation of headache (ie, medication overuse headache); may present as migrainelike daily headaches or as a marked increase in frequency of migraine attacks; detoxification and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary
Pregnancy-Lactation
Pregnancy
No adequate data are available on the developmental risk associated with use in pregnant women
Clinical considerations
Data suggest women with migraine may be at increased risk for preeclampsia and gestational hypertension during pregnancy
Animal data
In animal studies, adverse effects on development (increased incidences of fetal abnormalities, increased embryofetal and offspring mortality, decreased fetal body weight) occurred at maternal exposures less than (rabbit) or greater than (rat) those observed clinically
Lactation
There are no data on the presence in human milk, effects on breastfed infants, or effects on milk production
Excretion of lasmiditan and/or metabolites into milk, at levels ~3 times those in maternal plasma, was observed in lactating rats following oral administration
Interactions
Lasmiditan inhibits P-gp and breast cancer-resistant protein (BCRP); avoid coadministration
Owing to the potential for sedation, other cognitive and/or neuropsychiatric adverse reactions, and driving impairment, use with caution if used in combination with alcohol or other CNS depressants
Coadministration of lasmiditan and drugs (eg, SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone), over-the-counter medications (eg, dextromethorphan), or herbal supplements (eg, St. John’s wort) that increase serotonin may increase the risk of serotonin syndrome; use with caution in patients taking medications that increase serotonin.
In a drug interaction study, addition of a single lasmiditan 200-mg dose to propranolol decreased heart rate by an additional 5 bpm compared with propranolol alone, for a mean maximum of 19 bpm; use with caution in patients taking concomitant medications that lower heart rate
Adverse Effects
Side effects of Lasmiditan :
>10%
Dizziness (9-17%)
1-10%
Paresthesia (3-9%)
Sedation (6-7%)
Fatigue (4-6%)
Nausea and/or vomiting (3-4%)
Muscle weakness (1-2%)
<2%
Vertigo
Incoordination
Lethargy
Visual impairment
Feeling abnormal
Palpitations
Anxiety
Tremor
Restlessness
Sleep abnormalities (eg, sleep disturbance, abnormal dreams)
Muscle spasm
Limb discomfort
Cognitive changes
Confusion
Euphoric mood
Chest discomfort
Speech abnormalities
Dyspnea
Hallucinations
<1%
Hypersensitivity (eg, angioedema, rash, photosensitivity reaction)
Mechanism of Action
Lasmiditan binds with high affinity to the 5-HT1F receptor; it presumably exerts its therapeutic effects for acute migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown
Serotonin 5-HT1F agonists do not elicit a vasoconstrictive effect
Note
Reyvow 100 mg Tablets manufactured by ELI LILLY AND COMPANY. Its generic name is Lasmiditan. Reyvow is availble in United Arab Emirates.
Farmaco UAE drug index information on Reyvow Tablets is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.